Vicarious Surgical (RBOT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
12 Jun, 2026Executive summary
Special Meeting scheduled for July 20, 2026, to vote on an assignment for the benefit of creditors followed by voluntary dissolution and liquidation under a Plan of Dissolution, if deemed in the best interests of stockholders by the board.
Board unanimously recommends voting FOR the Assignment and Dissolution Proposal, which includes authorization to abandon the process if necessary.
The company faces recurring losses, negative cash flow, inability to raise capital, and unsuccessful attempts to sell the business, leading to the proposed dissolution.
Based on current liabilities and assets, it is unlikely that stockholders will receive any distribution from the liquidation.
Upon completion, the company will cease all business activities except those related to winding up and liquidating affairs, and intends to terminate its status as a public reporting company.
Voting matters and shareholder proposals
Only one proposal: approval of the Assignment and Dissolution, including the Plan of Dissolution, with board authorization to abandon if needed.
Each Class A share has one vote; each Class B share has 20 votes.
Approval requires a majority in voting power of outstanding common stock.
Abstentions count as votes against the proposal.
No other matters are expected to be acted upon at the meeting.
Board of directors and corporate governance
Board determined dissolution is in the best interests of stockholders after considering financial projections, debts, inability to raise capital, and lack of buyers.
Board retains discretion to abandon or modify the Plan of Dissolution without further stockholder action.
Board will select the Assignee to oversee liquidation; currently expected to be Resolution Financial Advisors or an affiliate.
Latest events from Vicarious Surgical
- Stockholders will vote on dissolving the company, with distributions to them considered unlikely.RBOT
Proxy filing22 Jun 2026 - Net loss narrowed to $7.3M in Q1 2026, but cash only funds operations through Q2 2026.RBOT
Q1 202630 Apr 2026 - Vote on a reverse stock split to support Nasdaq listing and investor access, with Board discretion.RBOT
Proxy filing23 Mar 2026 - Vote sought on a reverse stock split to support Nasdaq listing and broaden investor appeal.RBOT
Proxy Filing13 Mar 2026 - Net loss and expenses declined in 2025, with 2026 cash burn expected to decrease further.RBOT
Q4 20259 Mar 2026 - Robotic system targets untapped surgical markets with advanced intra-abdominal access and dexterity.RBOT
H.C. Wainwright 27th Annual Global Investment Conference3 Feb 2026 - All proposals, including director elections and key amendments, were approved without questions.RBOT
AGM 20241 Feb 2026 - Q2 2024 saw improved losses, $73.2M liquidity, and V1.0 system on track for fall integration.RBOT
Q2 20241 Feb 2026 - Operating expenses dropped 17% in Q3 and net loss narrowed as clinical milestones approach.RBOT
Q3 202414 Jan 2026